XyloCor Therapeutics
XyloCor Therapeutics is a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease. Their lead product candidate, XC001, aims to treat refractory angina and is in clinical development. XyloCor is pioneering one-time gene therapy to address unmet needs in patients with cardiovascular disease.
Buy Funded Startups lists
Funding Round: Series B
Funding Amount: $67.5M
Date: 07-Jan-2025
Investors: Jeito Capital, EQT, Fountain Healthcare Partners, Lumira Ventures
Markets: Biotechnology, Gene Therapy, Cardiovascular Disease
HQ: King of Prussia, Pennsylvania, United States
Founded: 2013
Website: http://xylocor.com/
LinkedIn: https://www.linkedin.com/company/xylocor-therapeutics-inc.
Crunchbase: https://www.crunchbase.com/organization/xylocor-therapeutics
Leave a Comment
Comments
No comments yet.